5-EAPB
5-EAPB is a benzofuran entactogen-stimulant, the N-ethyl homologue of 5-APB, sold as a research chemical after benzofurans like 6-APB were controlled. It is a serotonin-norepinephrine-dopamine releaser/reuptake inhibitor with MDMA-like effects, minimal human data, and cardiovascular plus serotonergic risk.
01 Overview
5-EAPB (5-(2-ethylaminopropyl)benzofuran) is part of the benzofuran family of MDMA-like designer drugs that emerged as legal alternatives to MDMA and to the earlier APB compounds. It is used orally for entactogenic and stimulant effects.
No clinical studies exist. Benzofurans are associated with serotonin toxicity, hyperthermia and cardiovascular events in case reports, and 5-EAPB is presumed to share these risks. Its long duration and potency are frequently underestimated by users.
02 Mechanism
Acts as a releasing agent and reuptake inhibitor of serotonin, norepinephrine and dopamine; benzofuran bioisostere of MDA/MDMA-type entactogens.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common (approximate, anecdotal) | 80–150 mg | Oral | User-reported; long onset invites dangerous redosing. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Entactogenic warmthMDMA-like empathy, sociability and mood elevation reported. | Moderate | Anecdotal | |
| StimulationIncreased energy and wakefulness. | Moderate | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Cardiovascular strainTachycardia and hypertension. | Moderate | Common | Anecdotal | |
| Serotonin toxicity / hyperthermiaRisk of serotonin syndrome and dangerous overheating, especially with other serotonergics or in hot environments. | Severe | Unknown; documented for benzofurans | Unconfirmed |